Nektar reports updated response data for immuno-oncology combo

Nektar Therapeutics (NASDAQ:NKTR) reported response data from 60 evaluable patients with solid tumors who were naïve to immunotherapy in the open-label, international Phase Ib/II PIVOT-02 trial evaluating the company's NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab. The data were released in

Read the full 405 word article

User Sign In